A meta-analysis of trials enrolling acute MI patients with PCI (<26% T2D patients) confirmed the reduction in infarct size and improvement in LVEF by treatment with GLP1-RA compared to placebo (Huang et al., 2017). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.